HAI TRINH: Open Payments
NPI 1295336782 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,510 in 70 payments from 15 companies in 2025. Trend: 2023 $995 · 2024 $1,497 · 2025 $1,510
Food & beverage: $1,510
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $371 |
| Otsuka America Pharmaceutical, Inc. | 14 | $331 |
| Alkermes, Inc. | 5 | $126 |
| Axsome Therapeutics, Inc. | 4 | $123 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $102 |
| Vanda Pharmaceuticals Inc. | 4 | $89 |
| Lundbeck LLC | 4 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $76 |
| Tris Pharma Inc | 2 | $46 |
| Bausch Health US, LLC | 2 | $36 |
Products named: REXULTI, VRAYLAR, LYBALVI, Auvelity, CAPLYTA, TRINTELLIX, Dyanavel XR, HETLIOZ.
Industry payments across TX — which companies pay providers there.
